Acticor: receivership proceedings extended

(CercleFinance.com) - Biopharmaceutical company Acticor Biotech has announced that the Paris Commercial Court has decided to extend its receivership proceedings, which it opened on August 6.


The purpose of these proceedings is to enable Acticor to evaluate all options for pursuing its development, as well as its search for financing and partners. It will also enable the company to finance its operations until January 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.